

A BETTER APPROACH FOR A BETTER ATOPIC DERMATITIS TRIAL

Atopic dermatitis is the most common inflammatory skin condition worldwide. Despite its prevalence, clinical assessments for atopic dermatitis are extremely complex. Between the various scoring scales used and the wide range of patients, consistency across a clinical study is a challenge.

STANDARDIZE RATER TRAINING

Our targeted atopic dermatology rater training standardizes clinician-reported outcome (ClinRO) scales, limits the augmentation of placebo responses, and improves assessment techniques. Designed and implemented by experienced clinician raters, SmartSignals™ Rater Training and Qualification prevents inter- and intra-rater variability from impacting your signal detection.

ELIMINATE BETWEEN-SCALE INCONSISTENCIES

Atopic dermatology trials often include multiple clinician-reported outcome scales, which can contain overlapping assessment areas such as body surface area (BSA) assessment. With approval of scale authors, Signant combined the three common scales (SCORAD, EASI, and BSA) into a single, custom assessment. Our novel implementation simplifies data collection by reducing the unnecessary need for duplicate assessments and decreasing inter-scale inconsistencies.

ASSESS DIVERSE SKIN TYPES PROPERLY

We've worked with leading dermatologists to create a unique set of reference and training images that represent the diversity of skin types required in global clinical trials.

IMPROVE IN-STUDY ENDPOINT RELIABILITY

Our centralized statistical monitoring of blinded data identifies outliers, patterns, inconsistencies, trends, and potential fraud so you can make the necessary adjustments. Led by experienced data experts and clinicians, our SmartSignals Blinded Data Analytics Solution provides actionable insights to reduce noise and improve the power to successfully detect signals.

ACCOMMODATE PEDIATRIC PATIENTS

Our flexible platform enables implementation of different patient-reported outcome instrument versions based on the individual's age as well as offers the caregiver access needed for younger patients.



At Signant, our SmartSignals solutions were designed specifically to meet the needs of atopic dermatitis sponsors, sites, and patients alike. To advance treatments, atopic dermatitis studies must use today's latest technology.

SIGNANT'S ATOPIC DERMATITIS EXPERIENCE IN THE PAST 5 YEARS

Phases




62
Trials



28
Languages



19,200+
Patients



SMARTSIGNALS™ TRIAL SOLUTIONS

eCOA | RTSM | eCONSENT | ENDPOINT RELIABILITY | BLINDED DATA ANALYTICS
RATER TRAINING & QUALIFICATION

MEET THE EXPERTS

Discuss your next atopic dermatitis trial with our subject matter experts, and we'll tailor our eCOA solution to fit your needs.



BILL BYROM, PhD

VP Product Intelligence & Positioning

Dr. Byrom has worked in the Pharmaceutical industry for 30 years and is the author of over 70 publications and two industry textbooks on electronic patient-reported outcomes (ePRO).



TODD EVERHART, MD

Clinical VP Internal Medicine

Dr. Everhart is board-certified in internal medicine and a fellow of the American College of Physicians with over 23 years of experience in the practice of medicine and over 12 years of experience in clinical development.



ALEX KALPADAKIS-SMITH, PhD

Scientific Advisor

Dr. Kalpadakis-Smith provides scientific expertise on capturing digital Outcome Assessments (eCOA) and integrating health devices. Her continuous research on the mobile technology needs within therapeutic indications helps to tailor our solutions.



JILL PLATKO, PhD

Senior Scientific Advisor

Dr. Platko is an expert in electronic Clinical Outcome Assessment (eCOA) systems. She began her career in biology-based scientific research and led projects at renowned institutions, such as the Whitehead Institute Center for Genome Research, and Massachusetts General Hospital.

CONTACT US TO LEARN HOW SIGNANT HEALTH CAN SUPPORT YOUR NEXT STUDY.